HOME >> BIOLOGY >> NEWS
Jefferson scientists use gene therapy to reverse heart failure in animals

(PHILADELPHIA) Heart researchers at the Center for Translational Medicine at Jefferson Medical College have used gene therapy to reverse heart failure in animals. In addition, they found that this gene therapy strategy had "unique and additive effects" to currently used, standard heart failure drugs called beta-blockers.

Reporting in the American Heart Association journal Circulation, researchers led by Walter J. Koch, Ph.D., director of the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy in the Department of Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, used a virus to carry the gene for a protein, S100A1, into the heart cells of rats with heart failure. The virus expressed the S100A1 gene only in heart cells and not in other organs, essentially making it a tailored therapy. After 18 weeks, those animals that received the gene therapy had significantly improved heart function compared to animals that did not receive the treatment.

Specifically, the Koch team, including Patrick Most, M.D., and Joseph Rabinowitz, Ph.D., also in Jefferson's Center for Translational Medicine, experimentally produced heart failure in the animals, which is characterized by a dramatic reduction in the heart's pumping ability. The scientists then delivered a modified adeno-associated virus (AAV) that contained the S100A1 gene to the heart's coronary arteries with the help of a novel heart-specific "gene promoter" that enabled the gene to be present only in heart cells.

The rats with heart failure were then followed for another two months, when their heart pumping function was monitored again. The animals that received the gene therapy had significantly better heart-pumping abilities compared to the pre-gene therapy level, and overall, the S100A1-treated rats had improved heart health. The researchers found this in both individual heart cells and in the whole
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
23-May-2007


Page: 1 2 3

Related biology news :

1. Jefferson scientists patent dramatically improves
2. Marker predicts pancreatic cancer outcome after surgery, Jefferson surgeon finds
3. Tiny genes may increase cancer susceptibility, Jefferson scientists find
4. Jefferson researchers discovery may change thinking on how viruses invade the brain
5. Jefferson scientists identify protein key to breast cancer spread, potential new drug target
6. Jefferson scientists find rabies-based vaccine could be effective against HIV
7. Jefferson scientists uncover gene mutation that cuts colon polyps, may suppress cancer
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Jefferson scientists find guardian genes choices crucial to stopping cancer process
10. Jefferson researchers uncover new way nature turns genes on and off
11. Jefferson researchers develop combined procedure for uterine preservation in treating fibroids

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/22/2020)... (PRWEB) , ... January 21, 2020 , ... ... Pozil to lead the company’s new Business Development Department. The move, which is ... Pozil had been previously serving as the company’s Senior Vice President where he ...
(Date:1/22/2020)... ... January 21, 2020 , ... ... transport validation strategies, supporting global regulatory applications, and executing global clinical trial ... Business Journal as a fastest growing company, and ISO 9001:2015 certification with ...
(Date:1/8/2020)... , ... January 08, 2020 , ... ... now offering complimentary overnight shipping to its nationwide practice network partners. Not ... also due to volume in its Network the biologics themselves are less expensive. ...
Breaking Biology News(10 mins):
(Date:1/24/2020)... RIDING, Va. (PRWEB) , ... January 24, 2020 ... ... and other innovations created by companies in biotechnology, diagnostics, therapeutics, laboratory and clinical ... lives of millions of people around the world. And as Slone Partners ...
(Date:1/22/2020)... ... January 21, 2020 , ... ... Taylor as Southern Midwest Region Industrial and Institutional (I&I) Account Manager. Darrell will ... , Darrell brings over 30 years of sales experience working across ...
(Date:1/10/2020)... ... January 09, 2020 , ... Phlexglobal, the leading provider ... of Cunesoft, a move that expands the company’s portfolio of best-of-breed technologies designed ... , Based in Munich, Germany, Cunesoft provides intelligent software and expert services for ...
(Date:1/7/2020)... ... January 07, 2020 , ... Absolute Antibody Ltd. , ... of its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models. ... hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research ...
Breaking Biology Technology:
Cached News: